Biomerica Share Price Today
(NASDAQ: BMRA)

Name: Biomerica Share Price Today (NASDAQ: BMRA) - Biomerica Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Biomerica share price is $0.67 & ₹58.27 as on 6 Mar 2025, 2.30 'hrs' IST

$0.67

▲

-0.01

(-0.74%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Biomerica share price in Dollar and Rupees. Guide to invest in Biomerica stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Biomerica, along with analyst recommendations, forecasts, and comprehensive financials.

Biomerica share price movements

Today's Low: $0.66
Today's High: $0.71
$0.67
1.91%
Downside
Day's Volatility :7.41%
Upside
5.61%
52 Weeks Low: $0.24
52 Weeks High: $1.27
$0.67
63.96%
Downside
52 Weeks Volatility :80.98%
Upside
47.24%

Biomerica (BMRA) Returns

Period	Biomerica Inc	Index (Russel 2000)
3 Months	87.24%	0.0%
6 Months	73.92%	0.0%
1 Year	-42.31%	0.0%
3 Years	-82.95%	-11.6%

Biomerica (BMRA) Key Statistics

in dollars & INR

Previous Close	$0.675
Open	$0.6753
Today's High	$0.7098
Today's Low	$0.6572
Market Capitalization	$5.5M
Today's Volume	$54.8K
52 Week High	$1.27
52 Week Low	$0.2415
Revenue TTM	$5.5M
EBITDA	$-6.4M
Earnings Per Share (EPS)	$-0.37
Profit Margin	-111.85%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-76.48%

How to invest in Biomerica Stock (BMRA) from India?

It is very easy for Indian residents to invest directly in Biomerica from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Biomerica stock in both Indian Rupees (INR) and US Dollars (USD). Search for Biomerica or BMRA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Biomerica or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Biomerica shares which would translate to 1.298 fractional shares of Biomerica as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Biomerica, in just a few clicks!

Returns in Biomerica (BMRA) for Indian investors in Rupees

The Biomerica stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Biomerica investment value today

Current value as on today

₹62,228

Returns

₹37,772

(-37.77%)

Returns from Biomerica Stock

₹42,735 (-42.74%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Biomerica (BMRA)

-44.69%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Investment in Biomerica Shares from India has dropped by -44.69% over the past 30 days, indicating reduced transactional activity.

-29%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Biomerica Stock from India on INDmoney has decreased by -29% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Biomerica

Granahan Investment Management Inc..
3.59%
Vanguard Group Inc
0.92%
BlackRock Inc
0.81%
Geode Capital Management, LLC
0.65%
TWO SIGMA SECURITIES, LLC
0.30%
State Street Corp
0.20%

Analyst Recommendation on Biomerica

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Biomerica(by analysts ranked 0 to 5 stars)

Based on 7 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Biomerica Stock (BMRA)

What analysts predicted

Upside of 1840.3%

Target:

$13.00

Current:

$0.67

Insights on Biomerica Stock (Ticker Symbol: BMRA)

Price Movement
In the last 1 month, BMRA stock has moved up by 33.4%
Decreasing Revenue
Revenue is down for the last 2 quarters, 1.80M → 1.63M (in $), with an average decrease of 9.5% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -1.91M → -950.0K (in $), with an average increase of 27.2% per quarter
BMRA vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 54.6% return, outperforming this stock by 98.8%
BMRA vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 135.7% return, outperforming this stock by 219.2%
Price to Sales
ForBMRA every $1 of sales, investors are willing to pay $2.1, whereas for Boston Scientific Corp., the investors are paying $9.1 for every $1 of sales.

BMRA Biomerica Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$5.2M	↓ 6.53%
Net Income	$-2.4M	↑ 63.26%
Net Profit Margin	-46.01%	↓ 19.67%

	FY20	Y/Y Change
Revenue	$6.7M	↑ 28.69%
Net Income	$-2.3M	↓ 2.26%
Net Profit Margin	-34.95%	↑ 11.06%

	FY21	Y/Y Change
Revenue	$7.2M	↑ 7.57%
Net Income	$-6.5M	↑ 176.57%
Net Profit Margin	-89.86%	↓ 54.91%

	FY22	Y/Y Change
Revenue	$18.9M	↑ 162.14%
Net Income	$-4.5M	↓ 29.96%
Net Profit Margin	-24.01%	↑ 65.85%

	FY23	Y/Y Change
Revenue	$5.3M	↓ 71.71%
Net Income	$-7.1M	↑ 57.58%
Net Profit Margin	-133.73%	↓ 109.72%

	FY24	Y/Y Change
Revenue	$5.4M	↑ 1.42%
Net Income	$-6.0M	↓ 16.27%
Net Profit Margin	-110.4%	↑ 23.33%

	Q3 FY23	Q/Q Change
Revenue	$1.7M	↑ 54.57%
Net Income	$-1.1M	↓ 36.84%
Net Profit Margin	-66.08%	↑ 95.64%

	Q4 FY23	Q/Q Change
Revenue	$1.6M	↓ 8.52%
Net Income	$-1.5M	↑ 33.13%
Net Profit Margin	-96.17%	↓ 30.09%

	Q1 FY24	Q/Q Change
Revenue	$1.0M	↓ 35.1%
Net Income	$-1.9M	↑ 27.27%
Net Profit Margin	-188.59%	↓ 92.42%

	Q2 FY24	Q/Q Change
Revenue	$1.1M	↑ 9.73%
Net Income	$-1.4M	↓ 25.91%
Net Profit Margin	-127.33%	↑ 61.26%

	Q3 FY24	Q/Q Change
Revenue	$1.8M	↑ 61.92%
Net Income	$-1.3M	↓ 7.39%
Net Profit Margin	-72.83%	↑ 54.5%

	Q4 FY24	Q/Q Change
Revenue	$1.6M	↓ 9.46%
Net Income	$-950.0K	↓ 27.81%
Net Profit Margin	-58.07%	↑ 14.76%

	FY19	Y/Y Change
Profit	$1.3M	↓ 26.36%

	FY20	Y/Y Change
Profit	$1.8M	↑ 37.91%

	FY21	Y/Y Change
Profit	$497.0K	↓ 72.11%

	FY22	Y/Y Change
Profit	$3.0M	↑ 499.1%

	FY23	Y/Y Change
Profit	$446.0K	↓ 85.02%

	FY24	Y/Y Change
Profit	$611.0K	↑ 37.0%

	Q3 FY23	Q/Q Change
Profit	$412.0K	↑ 1330.21%

	Q4 FY23	Q/Q Change
Profit	$325.0K	↓ 21.12%

	Q1 FY24	Q/Q Change
Profit	$-149.0K	↓ 145.85%

	Q2 FY24	Q/Q Change
Profit	$20.0K	↓ 113.42%

	Q3 FY24	Q/Q Change
Profit	$289.0K	↑ 1345.0%

	Q4 FY24	Q/Q Change
Profit	$437.0K	↑ 51.21%

	FY19	Y/Y Change
Operating Cash Flow	$-2.2M	↑ 91.11%
Investing Cash Flow	$-171.1K	↑ 31.27%
Financing Cash Flow	$1.9M	↑ 47.37%

	FY20	Y/Y Change
Operating Cash Flow	$-4.3M	↑ 91.51%
Investing Cash Flow	$-118.9K	↓ 30.5%
Financing Cash Flow	$12.4M	↑ 548.73%

	FY21	Y/Y Change
Operating Cash Flow	$-5.3M	↑ 22.2%
Investing Cash Flow	$-295.6K	↑ 148.54%
Financing Cash Flow	$1.1M	↓ 91.0%

	FY22	Y/Y Change
Operating Cash Flow	$-480.5K	↓ 90.85%
Investing Cash Flow	$-170.3K	↓ 42.37%
Financing Cash Flow	$2.4M	↑ 115.0%

	FY23	Y/Y Change
Operating Cash Flow	$-5.5M	↑ 1039.15%
Investing Cash Flow	$-78.0K	↓ 54.21%
Financing Cash Flow	$9.4M	↑ 292.15%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-1.7M	↑ 73.89%
Investing Cash Flow	$-63.0K	↑ 345.54%
Financing Cash Flow	$-71.0K	↓ 100.97%

Biomerica Technicals Summary

Sell

Neutral

Buy

Biomerica is currently in a neutral trading position according to technical analysis indicators.

Biomerica (BMRA) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biomerica Inc	43.46%	73.92%	-42.31%	-82.95%	-77.87%
Medtronic Plc	2.26%	4.07%	8.74%	-12.76%	0.68%
Edwards Lifesciences Corp.	0.07%	8.12%	-19.19%	-34.12%	12.08%
Boston Scientific Corp.	0.07%	27.33%	53.68%	143.5%	203.93%
Stryker Corporation	-0.63%	8.92%	9.84%	53.87%	125.87%
Abbott Laboratories	7.11%	21.64%	15.28%	15.75%	78.63%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biomerica Inc	NA	NA	0.0	0.0	-0.76	-0.39	NA	0.32
Medtronic Plc	28.75	28.75	1.87	5.45	0.08	0.05	0.03	38.49
Edwards Lifesciences Corp.	30.5	30.5	5.57	2.45	0.17	0.08	NA	16.99
Boston Scientific Corp.	83.9	83.9	1.85	2.86	0.09	0.05	NA	14.76
Stryker Corporation	50.89	50.89	2.85	13.49	0.15	0.07	0.01	54.1
Abbott Laboratories	18.34	18.34	2.52	5.15	0.31	0.06	0.02	27.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biomerica Inc	Buy	$5.5M	-77.87%	NA	-111.85%
Medtronic Plc	Buy	$120.9B	0.68%	28.75	12.83%
Edwards Lifesciences Corp.	Buy	$42.0B	12.08%	30.5	76.75%
Boston Scientific Corp.	Buy	$154.8B	203.93%	83.9	11.07%
Stryker Corporation	Buy	$150.7B	125.87%	50.89	13.25%
Abbott Laboratories	Buy	$238.6B	78.63%	18.34	31.95%

About Biomerica

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California.

Organization	Biomerica
Employees	64
CEO	Mr. Zackary S. Irani
Industry	Health Technology

Management People of Biomerica

Name	Title
Mr. Zackary S. Irani	CEO & Director
Mr. Allen C. Barbieri	Executive Vice-Chairman of the Board & Corporate Secretary
Mr. Gary Lu CPA	Principal Accounting Officer & CFO
Ms. Lucy Liu Ph.D.	Director of Manufacturing & Technical Operations

Important FAQs about investing in BMRA Stock from India :

What is Biomerica share price today?

Biomerica share price today stands at $0.67, Open: $0.68 ; Previous Close: $0.68 ; High: $0.71 ; Low: $0.66 ; 52 Week High: $1.27 ; 52 Week Low: $0.24.

The stock opens at $0.68, after a previous close of $0.68. The stock reached a daily high of $0.71 and a low of $0.66, with a 52-week high of $1.27 and a 52-week low of $0.24.

Can Indians buy Biomerica shares?

Yes, Indians can invest in the Biomerica (BMRA) from India.

With INDmoney, you can buy Biomerica at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Biomerica at zero transaction cost.

How can I buy Biomerica shares from India?

It is very easy to buy Biomerica from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Biomerica (BMRA) be purchased?

Yes, you can buy fractional shares of Biomerica with INDmoney app.

What are the documents required to start investing in Biomerica stocks?

To start investing in Biomerica, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.